Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Dynavax Is Surging 6.1% Today

By Todd Campbell – Jul 14, 2020 at 3:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.

What happened

Dynavax's (DVAX -3.41%) shares are climbing 6.1% as of 3:35 p.m. EDT on Tuesday after the company announced the first patients have been dosed in an early stage trial evaluating a COVID-19 vaccine containing its CpG 1018 adjuvant.

So what

Medicago, a private company owned by Mitsubishi Tanabe Pharma (MTZXF) and Philip Morris International (PM -2.18%), is evaluating whether Dynavax's adjuvant enhances immune responses to its plant-derived COVID-19 vaccine.

A syringe resting next to a jig saw puzzle piece displaying the word vaccine.

Image source: Getty Images.

The phase 1 trial is enrolling 180 people to evaluate three dose levels of Medicago's plant-derived coronavirus-like particle COVID-19 vaccine. Participants will receive either Medicago's vaccine on its own or in combination with Dynavax's adjuvant or an adjuvant made by competitor GlaxoSmithKline (GSK -0.43%).

The healthcare company expects preliminary safety and efficacy data from this trial in October. If successful, Medicago plans to initiate a phase 3 trial soon thereafter.

Now what

Dynavax isn't developing its own vaccine, but it has inked deals with other companies to incorporate its adjuvant into their efforts, giving it multiple shots on goal.

There's no telling if Dynavax's adjuvant will work, but the fact it's already used in Dynavax's FDA-approved hepatitis B vaccine -- Heplisav-B -- is encouraging. 

Nonetheless, since a flurry of COVID-19 vaccine research is under way and it remains to be seen which projects pan out or if one vaccine works better than another, investors might want to approach Dynavax cautiously until more data is available. 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.